ABSTRACT

Introduction: The oral route still represents the most popular way of administering drugs; nowadays oral administration faces new challenges, in particular with regards to the delivery of APIs that are poorly absorbed and sensitive to degradation such as macromolecules and biotechnological drugs. Nanoparticles are promising tools for the efficient delivery of these drugs to the gastrointestinal tract.

Areas covered:Approaches and techniques for the formulation of drugs, with particular focus on the preparation of polysaccharide nanoparticles obtained by non-covalent interactions.

Expert opinion:Polysaccharide-based nanoparticulate systems offer the opportunity to address some of the issues posed by biotechnological drugs, as well as by small molecules, with problems of stability/intestinal absorption, by exploiting the capability of the polymer to establish non-covalent bonds with functional groups in the chemical structure of the API.

This area of research will continue to grow, provided that these drug delivery technologies will efficaciously be translated into systems that can be manufactured on a large scale under GMP conditions. Industrial scale-up represents the biggest obstacle to overcome in view of the transformation of very promising results obtained on lab scale into medicinal products. To do that, an effort toward the simplification of the process and technologies is necessary.

摘要

简介：口服途径仍然是最受欢迎的药物管理方式。如今，口服给药面临着新的挑战，特别是在递送吸收不良且对降解敏感的API（例如大分子和生物技术药物）方面。纳米颗粒是有效地将这些药物递送至胃肠道的有前途的工具。

涵盖的领域：药物配制的方法和技术，特别着重于通过非共价相互作用获得的多糖纳米颗粒的制备。

专家意见：基于多糖的纳米颗粒系统通过利用聚合物建立非共价键的能力，提供了解决生物技术药物以及小分子带来的一些问题的机会，这些问题具有稳定性/肠道吸收问题在API的化学结构中带有官能团。

只要将这些药物输送技术有效地转化为可以在GMP条件下大规模生产的系统，这一研究领域将继续增长。鉴于将实验室规模获得的非常有希望的结果转化为医药产品，工业规模扩大是要克服的最大障碍。为此，必须努力简化工艺和技术。